Clinical Trial Update: A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluating MEDI-551 in adults with relapsed or refractory chronic lymphocytic leukemia; the trial has completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: COMPLETED | Results posted: 2017-05-31